News

Multiple myeloma is a cancer of the plasma cells in which abnormal plasma cells multiply uncontrollably in the bone marrow and occasionally in other parts of the body. It is the second most common ...
Stoboclo and Osenvelt, FDA-approved biosimilars of Prolia and Xgeva, are now available in the U.S. for variois cancers and ...
By MELINDA J. OVERSTREET for Glasgow News 1 In September 2023, he had been fighting a cold for weeks and weeks. His immune ...
Celltrion USA today announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® ...
Multiple myeloma begins when abnormal cells multiply and grow uncontrollably in a person’s bone marrow, crowding out healthy ...
For decades, the diagnosis of multiple myeloma required evidence of end-organ damage characterized by myeloma-defining events (MDEs) known as CRAB: C=Hypercalcemia R=Renal insufficiency A=Anemia B ...
Bone lesions and soft spots that occur because of multiple myeloma are difficult to treat. They may cause continued fractures, even if the cancer itself has gone into remission.
Bone Pain and Fractures Bone pain, typically in the spine or ribs but possibly in any bone, is often one of the earliest signs of multiple myeloma. Myeloma cells stimulate cells that break down ...
Fresenius Kabi’s fifth and sixth biosimilars Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht) have launched in the ...
Dimitrios Christoulas; Evangelos Terpos; Meletios A Dimopoulos Disclosures Expert Rev Hematol. 2009;2 (4):385-398.
EXCLUSIVE: A top doctor has shared five common symptoms which could be a sign that something is seriously wrong.
Fresenius announced that its operating company, Fresenius Kabi, has introduced two new biosimilars – Conexxence ...